Xenon Pharmaceuticals Inc. XENE R2K
Healthcare · Biotechnology · Canada
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
READ MORE ›$54.73
+89.71% 1Y
Market & Price
Market Cap
$5.29B
Current Price
$54.73
High / Low (52W)
$62.76 / $28.85
Beta
0.65
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$7.27
Price to Book
7.53
P/S
inf
EV/EBITDA
-10.25
Dividend Yield
-
Profitability & Returns
ROCE
-63.09%
ROE
-37.53%
ROA
-24.22%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-1.17
EPS (TTM)
$-4.70
Balance Sheet & Liquidity
Debt/Equity
0.56
Quick Ratio
27.52
Current Ratio
27.79
Debt
$7.49M
Total Assets
$633.16M
Current Assets
$560.65M
Working Capital
$518.86M
Ownership
Promoter Holding
0.12%
Chg in Prom Hold
-
FII / Inst Holding
107.22%
Chg in FII Hold
-0.33%
Financial Snapshot
Enterprise Value
$4.20B
Total Revenue (TTM)
$0
EBITDA
$-410.19M
Free Cash Flow
$-186.27M
Operating Cash Flow
$-306.36M
Shares Outstanding
96.67M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-7.36%
Profit 5Y
-58.63%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -7.4% CAGR over 5 years.
- Earnings shrank at -58.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XENE Xenon Pharmaceuticals Inc. R2K | 54.73 | - | $5.29B | - | -63.09% | -37.53% | -7.36% | -58.63% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 264.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.50M | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.24M | 94.23M | 96.34M | 109.77M | 112.33M |
| Operating Income | 8.66M | 35.00K | -6.14M | 199.00K | -820.00K | -2.60M | -5.66M | -6.37M | -7.33M | -5.46M | -7.99M | -7.89M | -8.64M | -8.05M | -7.81M | -7.59M | -14.19M | -11.76M | -10.51M | -8.95M | -8.03M | -646.00K | -9.70M | -16.06M | -22.50M | -15.60M | -17.37M | -30.32M | -38.13M | -49.05M | -55.62M | -55.68M | -59.04M | -69.10M | - | -72.74M | -94.23M | -96.34M | -109.77M | -112.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -72.08M | -93.60M | -95.69M | -109.16M | -111.74M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -64.62M | -85.33M | -90.22M | -104.72M | -104.87M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 427.00K | -626.00K | 677.00K | 538.00K | -2.57M |
| Net Income | 9.19M | - | -9.16M | 1.17M | -3.83M | -3.94M | -3.26M | -6.02M | -7.71M | -6.00M | -7.52M | -7.38M | -7.74M | -8.06M | -3.75M | -7.80M | -14.38M | -11.34M | -10.01M | -8.87M | -7.48M | -175.00K | -8.86M | -15.76M | -22.11M | -15.45M | -19.67M | -31.16M | -37.15M | -41.73M | -47.46M | -48.46M | -47.93M | -57.92M | - | -65.05M | -84.71M | -90.90M | -105.26M | -102.30M |
| Diluted EPS | 1.69 | 0.13 | -0.64 | -0.07 | -0.27 | -0.27 | -0.23 | -0.42 | -0.51 | - | -0.43 | -0.41 | -0.43 | -0.45 | -0.21 | -0.45 | -0.63 | -0.42 | -0.37 | - | - | 0.00 | - | - | -0.51 | -0.36 | -0.35 | -0.55 | -0.57 | -0.63 | -0.72 | -0.73 | -0.62 | -0.75 | - | -0.83 | -1.07 | -1.15 | -1.31 | -1.17 |
| R&D Expense | 3.22M | - | 3.43M | 3.67M | 3.79M | - | 4.36M | 5.10M | 5.96M | - | 5.90M | 6.11M | 7.16M | - | 5.57M | 5.42M | 6.25M | 9.14M | 8.21M | 9.75M | 11.79M | 10.72M | 13.04M | 16.31M | 18.38M | 18.89M | 19.36M | 22.15M | 29.43M | 39.52M | 44.04M | 42.88M | 44.25M | 49.70M | 56.97M | 61.20M | 74.98M | 77.05M | - | 88.51M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 311.00K | - | - | - | - | 9.43M | 0 | 0 | 7.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 138.58M | 214.05M | 279.30M | 380.57M |
| Operating Income | -3.15M | 9.71M | 11.11M | -9.36M | -24.82M | -32.58M | -38.04M | -42.82M | -31.30M | - | -129.14M | -214.05M | -279.30M | -373.07M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -127.74M | -211.99M | -276.74M | -370.53M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -125.25M | -182.69M | -238.42M | -344.89M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 118.00K | -292.00K | -4.09M | 1.02M |
| Net Income | -4.30M | 12.03M | 13.02M | -15.75M | -23.00M | -30.70M | -34.50M | -41.59M | -28.84M | - | -125.37M | -182.39M | -234.33M | -345.91M |
| Diluted EPS | -3.24 | 1.91 | 3.28 | -1.10 | -1.48 | -1.72 | -1.63 | - | -0.81 | - | -2.06 | -2.73 | -3.01 | -4.36 |
| R&D Expense | 10.46M | 12.30M | 11.77M | 15.15M | 19.83M | 25.57M | 23.63M | 38.84M | 50.52M | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
Compounded Sales Growth
| 5 Years: | -7.36% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -58.63% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +89.71% |
| 6 Months: | +24.56% |
| 3 Months: | +26.60% |
| 1 Month: | -1.83% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 54.49M | 87.42M | 63.95M | 67.49M | 46.12M | 122.43M | 147.70M | 189.19M | - | 754.15M | 964.80M | 798.14M | 633.16M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 600.30M | 644.96M | 635.26M | 560.65M |
| Cash & Equivalents | 13.93M | 60.16M | 37.95M | 72.03M | 58.65M | 17.09M | 20.49M | 67.75M | 24.75M | 45.01M | - | 57.24M | 148.64M | 142.71M | 199.16M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 986.00K | 874.00K | 1.47M | 1.37M |
| Total Liabilities | - | - | 30.37M | 14.64M | 2.92M | 3.59M | 10.19M | 19.13M | 55.72M | 17.83M | - | 32.65M | 36.88M | 43.24M | 51.40M |
| Current Liabilities | - | - | 18.20M | 14.29M | 2.78M | 3.59M | 4.08M | 4.12M | 43.38M | 14.78M | - | 22.70M | 27.27M | 35.59M | 41.79M |
| Long Term Debt | - | - | - | - | - | - | 6.10M | 15.01M | 10.89M | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 10.44M | 10.90M | 9.02M | 7.94M |
| Total Equity | -86.32M | -89.86M | -78.37M | 72.78M | 61.03M | 63.90M | 35.93M | 103.30M | 91.98M | 171.35M | - | 721.50M | 927.92M | 754.90M | 581.76M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 62.59M | 75.37M | 76.42M | 80.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -28.73M | -34.72M | -4.71M | -48.12M | - | -101.03M | -151.11M | -181.39M | -279.12M |
| Investing Cash Flow | - | - | - | - | - | 24.29M | -28.99M | -66.21M | -16.82M | - | -293.40M | -111.39M | 165.00M | 218.00M |
| Financing Cash Flow | - | - | - | - | - | 7.07M | 111.59M | 27.52M | 85.80M | - | 278.47M | 353.52M | 12.13M | 117.11M |
| Capital Expenditure | -526.00K | -156.00K | -1.53M | -551.00K | -279.00K | -315.00K | -507.00K | -1.24M | -2.64M | - | -2.89M | -5.62M | -3.08M | -799.00K |
| Free Cash Flow | - | - | - | - | - | -29.04M | -35.23M | -5.95M | -50.76M | - | -103.92M | -156.73M | -184.46M | -279.92M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -115.96M | 91.03M | -4.26M | 55.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -10,474.3% | - | - | - | - | -1,368.9% | - | - | -4,974.3% |
| Net Margin % | - | - | - | - | - | -9,872.7% | - | - | - | - | -1,328.9% | - | - | -4,612.1% |
| ROE % | 4.8% | -15.4% | 17.9% | -25.8% | -36.0% | -85.4% | -33.4% | -45.2% | -16.8% | - | -17.4% | -19.7% | -31.0% | -59.5% |
| ROCE % | - | 26.8% | 15.2% | -15.3% | -38.8% | -77.5% | -32.2% | -41.0% | -17.9% | - | -17.7% | -22.8% | -36.6% | -63.1% |
Shareholding Pattern
Insiders
0.12%
Institutions
107.22%
Public Float
107.35%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 11.19% | 10.82M | $592.10M |
| 2 | Avoro Capital Advisors LLC | 5.98% | 5.78M | $316.22M |
| 3 | Blackrock Inc. | 5.83% | 5.64M | $308.68M |
| 4 | Wellington Management Group, LLP | 5.00% | 4.83M | $264.33M |
| 5 | Driehaus Capital Management, LLC | 4.65% | 4.49M | $245.83M |
| 6 | Polar Capital Holdings PLC | 4.56% | 4.41M | $241.10M |
| 7 | Janus Henderson Group PLC | 4.32% | 4.18M | $228.55M |
| 8 | Capital International Investors | 2.77% | 2.67M | $146.39M |
| 9 | Citadel Advisors Llc | 2.74% | 2.65M | $145.20M |
| 10 | JPMORGAN CHASE & CO | 1.99% | 1.92M | $105.28M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XENE
No recent headlines available.